Alzheimer's Disease Drug Discovery Services

Alzheimer's disease (AD) is inextricably linked to the aging process, and its incidence is rising dramatically as the global population ages. The disease is associated with a complex interplay of biological changes in the brain that occur with age. The drug development of Alzheimer's disease is diversified. An array of agents targeting various age-associated biological processes is also useful for Alzheimer's disease.

Fig. 1 Biology of Alzheimer's disease including many biological changes relevant to aging of multiple organ systems. (Cummings J, et al., 2023)

CD BioSciences is committed to offering drug discovery services that target the underlying mechanisms of Alzheimer's disease, particularly through the lens of aging-related pathways.

Alzheimer's Disease Drug Discovery Services Based on Aging Mechanisms

Drug discovery targeting inflammaging

Inflammaging, a phenomenon characterized by chronic, low-grade inflammation that accompanies aging, has emerged as a significant factor in the pathogenesis of Alzheimer's disease. At CD BioSciences, we highlight the role of pro-inflammatory cytokines and chemokines in disease progression. We offer sophisticated screening platforms to help clients identify novel drugs that modulate the inflammatory response, thereby ameliorating Alzheimer's disease-related neuropathology.

Drug discovery targeting synaptic plasticity

The decline of synaptic plasticity is a hallmark of Alzheimer's disease and aging. Our drug discovery services focus on identifying drugs that can enhance synaptic plasticity by targeting key signaling pathways. We also provide high-throughput screening of drugs that can modulate neurotransmitter release and receptor function, thereby restoring cognitive function in Alzheimer's disease models.

Drug discovery targeting aging-related epigenetic changes

We harness our expertise in epigenetic alterations to discover novel therapeutic targets for Alzheimer's disease, ranging from  DNA methylation and histone modification to non-coding RNA expression. By developing targeted demethylating agents or small molecules that affect DNA methyltransferase activity, we aim to restore normal methylation patterns. We are actively investigating several histone deacetylase (HDAC) inhibitors that have shown potential in preclinical models to enhance cognitive function and restore synaptic integrity. Additionally, we help clients develop oligonucleotide-based therapies that can inhibit or mimic the activity of target RNA to restore normal cellular functions disrupted in Alzheimer's disease.

Drug Categories We Can Discovery Services for Alzheimer's Disease

CD BioScience offers a comprehensive suite of drug discovery services for Alzheimer's disease, spanning various drug categories. Below are some of the key categories we specialize in:

• Small molecule drugs. Our discovery services focus on identifying novel small molecules that can cross the blood-brain barrier and target specific pathological mechanisms of Alzheimer's disease. We help clients develop small molecules that can be used as inhibitors of amyloid-beta production, aggregation, and clearance, as well as modulators of tau phosphorylation.
• Biologics. Our team is engaged in helping clients develop biologics, such as monoclonal antibodies that target amyloid-beta plaques and tau proteins. Our biologics are designed to break down pathological aggregates and modulate immune responses in the brain. We also use innovative gene-editing technologies, such as CRISPR/Cas9, as effective gene therapy approaches for Alzheimer's disease.

CD BioSciences is dedicated to pushing the boundaries of Alzheimer's disease drug discovery by adopting a multifaceted approach that targets aging-related mechanisms. If you are interested in our services, please feel free to contact us or make an online inquiry.

Reference

1. Cummings J, et al. Geroscience and Alzheimer's Disease Drug Development. J Prev Alzheimers Dis, 2023, 10 (4): 620-632.